Hemostemix Inc. ($HEM), a pioneer in regenerative medicine, harnesses the power of blood-derived stem cells for therapeutic purposes. With its flagship product, ACP-01, offering a personalized approach to treatment, $HEM is poised to revolutionize the field of healthcare.Boasting a market capitalization of $3.92 million or more.

Know more: https://finance.yahoo.com/quote/HEM.V?p=HEM.V